The Development of Oral Therapeutic Vaccine Against Cancer and Working Out on the Fast Testing of Immunogenic and Oncolytic Effector Antigens

Abstract

In the study of “the herd immunity”, it was found that antigenic “late” proteins L1 of human papillomavirus of types 6,16,18,31 and 45, “early” proteins E2, E6 and E7 induced the generation of interferon, CD4/CD8 T lymphocytes and T cell receptors, as well as apoptotic enzymes: granzyme B, perforin and granulysin in mice peripheric mononuclear blood cells and in splenocytes (according to Elispot). Cancer HeLa cells provoked tumour formation in mice testis and in intact lungs in a month after injection and in isolated lungs after 1–2 days of inoculation. “Early” protein E2, L-amino acid oxidase and D-amino acid oxidase blocked the growth of HeLa cells in vitro, working as an effector. There was the activation of the generation of interferon, immunogenic T lymphocytes as well as apoptotic enzymes: granzyme B, perforin and granulysin in blood, spleen and lung T lymphocytes in tumours of isolated lungs mice treated with HeLa cells. Even when anti-PD-L1 antibody (“checkpoint” control receptor for cancer blocking) was added to isolated tumorigenic mice lung, regardless of the presence of HeLa cells, there was the induction of the immunogenicity. The testing of immunogenic and oncolytic activities of antigens via isolated lung tumour formation lasted 5–7 days including Elispot and HeLa inoculation and provided rapid analysis of immunogenic effector activity and tumour suppressors.